US Johnson & Johnson says it can provide 20M vaccine doses by late March
Bloody Sunday plans, defining pandemics, teacher dilemmas: News from around our 50 states
How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.
Johnson & Johnson can deliver 20 million doses of its single-shot coronavirus vaccine to the U.S. government by the end of March, an executive.
“Assuming necessary regulatory approvals relating to our manufacturing processes, our plan is to begin shipping immediately upon emergency use authorization, and deliver enough single-doses by the end of March to enable the vaccination of more than 20 million Americans,” Johnson & Johnson’s Richard Nettles, vice president of medical affairs for the company's pharmaceutical unit Janssen, will tell a House Energy & Commerce subcommittee Tuesday.
Here's how severe weather is affecting Covid-19 vaccinations in these states
The frigid temperatures, snow and ice that have devastated parts of the country are having an impact on Covid-19 vaccinations, delaying deliveries and appointments for shots. © David Ryder/Getty Images A skier makes their way down a hill on February 13, 2021 in Seattle, Washington. A large winter storm dropped heavy snow across the region.
The company has applied to the Food and Drug Administration for emergency authorization. FDA is expected to grant that as early as this weekend, after an expert FDA panel convenes Friday to discuss the effectiveness and safety of J&J’s vaccine.
Why it matters: White House officials had cautioned that initial supply of the Johnson & Johnson vaccine would be limited because of production problems, although the company has said it will meet its agreement to supply the U.S. with 100 million doses by the end of June.
Video: Fmr. FDA Commissioner: Vaccine supply could exceed demand as soon as April (NBC News)
“We are confident in our plans to deliver 100 million single-dose vaccines to the United States during the first half of 2021, and we are continuing to partner with the U.S. government to explore all options to accelerate delivery,” Nettles will say.
The vaccine is 66 percent effective against the virus overall, but showed just 57 percent efficacy in a trial in South Africa, where a problematic strain, B.1.315, has spread widely. That strain has been reported in 10 U.S. states.
What’s next: The House panel will also hear from executives of Pfizer, Moderna, AstraZeneca and Novavax on ways the major vaccine manufacturers are scaling up production to meet the country’s vaccine demands.
Pfizer and Moderna each have pledged 300 million doses this year.
U.S. Boosts Dose Shipments; J&J Seeks EU Clearance: Virus Update .
The Biden administration is boosting vaccine shipments by 23% and doubling the number of shots distributed through pharmacies. U.S. cases and hospitalizations are dropping dramatically, suggesting that measures to interrupt transmission are working. © Bloomberg Health care workers prepare to prone a patient in the Covid-19 Intensive Care Unit (ICU) overflow area at Providence Holy Cross Medical Center in Mission Hills, California, U.S., on Friday, Feb. 5, 2021. California’s 14-day positive test rate dropped to 6.6%, down from 12.7% a month ago and the lowest since Nov. 30.